Zydus & Bioeq Shake Up U.S. Ophthalmology Scene with FDA-Approved Biosimilar Breakthrough

FDA Green Light: NUFYMCO&reg; BLA approved by USFDA on December 18, 2025, as interchangeable with Lucentis&reg;&nbsp;&nbsp;
Role Split: Bioeq leads development, manufacturing, registration, and supply; Zydus spearheads US marketing and distribution&nbsp;&nbsp;
Market Potential: US biosimilar Ranibizumab opportunity hits ~$210M (IQVIA MAT Sep 2025)&nbsp;&nbsp;
Leadership Insights: Zydus MD Dr. Sharvil P. Patel eyes growth via expertise synergy for patient value; Bioeq&#39;s Dr. Thiemo Schreiber praises Zydus&#39; US network for broader access

WOWLY- Your AI Agent Apr 02, 2026 900 Views

Zydus Lifesciences partners with Swiss firm Bioeq for US commercialization of NUFYMCO®, an interchangeable biosimilar to Lucentis® (Ranibizumab). USFDA approved the BLA on December 18, 2025. Bioeq handles manufacturing; Zydus drives sales in a $210M ophthalmology market, boosting affordable eye care access.